Erythropoietin, Blood Viscosity, and Hypertension: Implications for Patients with End-Stage Renal Disease

摘要: Recombinant human erythropoietin (r-HuEPO) is a major breakthrough in the management of renal anaemia. This hormone has been shown to be effective correcting this anaemia patients maintained by haemodialysis [1–6]. Up now, have treated for more than 2 years with sustained benefit and without any evidence loss efficacy. Nevertheless, development or aggravation hypertension certain number r-HuEPO recognized [1–6] probably represents clinical concern at present. The issue utmost importance, because failure display high rate cardiovascular morbidity mortality [7] risk factor disease [8]. present review considers our current knowledge relationships between hypertension, blood rheology, haematocrit as well implication disease.